LOGIN  |  REGISTER
Astria Therapeutics
Cue Biopharma

Brookdale Senior Living Reports June 2023 Occupancy

July 11, 2023 | Last Trade: US$4.88 0.17 -3.37

NASHVILLE, Tenn., July 11, 2023 /PRNewswire/ -- Brookdale Senior Living Inc. (NYSE: BKD) reported today its consolidated occupancy for June 2023.

Brookdale’s Consolidated Occupancy

June 2023 Observations:

  • June weighted average occupancy increased 160 basis points year-over-year, from 75.2% in 2022 to 76.8% in 2023. This represented a 20 basis point sequential increase compared to May 2023.
  • Achieved twenty consecutive months of year-over-year weighted average occupancy growth.
  • Weighted average occupancy increased sequentially each month within the quarter and the second quarter weighted average occupancy of 76.5% represented 190 basis points of year-over-year growth and 20 basis points of sequential growth compared to the first quarter 2023.

About Brookdale Senior Living

Brookdale Senior Living Inc. is the nation's premier operator of senior living communities. The Company is committed to its mission of enriching the lives of the people it serves with compassion, respect, excellence, and integrity. The Company, through its affiliates, operates independent living, assisted living, memory care, and continuing care retirement communities. Through its comprehensive network, Brookdale helps to provide seniors with care and services in an environment that feels like home. The Company's expertise in healthcare, hospitality, and real estate provides residents with opportunities to improve wellness, pursue passions, and stay connected with friends and loved ones. Brookdale, through its affiliates, operates and manages 672 communities in 41 states as of June 30, 2023, with the ability to serve more than 60,000 residents. Brookdale's stock trades on the New York Stock Exchange under the ticker symbol BKD. For more information, visit brookdale.com or connect with Brookdale on Facebook or Twitter.

 

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page